Yokohama, October 12, 2022 –  Ginward and Gold Nest Capital participate in the 2023 edition of BioJapan, the Asia’s premier event for the global biotechnology industry. Featuring a twinned exhibition, seminars and a large-scale partnering platform, the conference brings together over 900 companies seeking to forge new partnerships. Besides a high number of universities, research organisations, and biotechs, almost every top pharma in Japan participates in BioJapan, making the event is well-poised as a venue for discovering alliances with Japanese organisations.

Through our collaborative work and support from the Japan Bioindustry Association (JBA), the conference organiser, we are able to set up our booth and present our activities to conference participants through the whole 3-day event. We are joined by three innovative life science companies from Europe, including two of our portfolio companies: Dynamic Biosensors, BiosanaPharma and CellBox Solutions.

Numerous business discussions are engaged with potential Japanese partners regarding our consulting/investment activities, and to form new partnerships for our companies. This presence also allows us to be in direct contact and explore the Japanese biotech ecosystem, and to witness its development and growing internationalisation through the actions of all stakeholders.